The aim of the trial is to examine the clinical response of metastatic melanoma following BNCT with BPA.
The trial contains an optional biodistribution sub-study , which is done if operable metastases are removed prior BNCT. BNCT is applied in 2 fractions at the HFR in Petten. In cases of diffuse brain metastases the whole brain is irradiated homogeneously using 5 irradiation beams from different directions. Up to now 4
patients suffering from multiple brain metastases (more than 20) have been included. In all cases we observed a partial response or no change in the irradiated volume. However, none of the patients survived more than 3 months. The pharmacokinetic of the BPA can be predicted very precisely using a two-compartment model.
The treatment can be performed safely.
SAUERWEIN Wolfgang;
MOSS Raymond;
STECHER-RASMUSSEN Finn;
NIEVAART Victor Alexander;
GRABBE Stephan;
HEIMANS Jan;
COLLETTE Laurence;
VAN LOENEN Arie;
BUEHRMANN Sandra;
ROCA Antoaneta;
HOVING Anton;
RASSOW Juergen;
WITTIG Andrea;
2006-11-17
International Society for Neutron Capture Therapy: ISNCT
JRC35042
https://publications.jrc.ec.europa.eu/repository/handle/JRC35042,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|